The benefits and challenges associated with the use of drug delivery systems in cancer therapy

Biochemical Pharmacology

Volumn 80, Issue 5, 2010, Pages 762-770

  Cukierman, Edna ^a   Khan, David R ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b WEST TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Chemotherapy; Drug delivery; Extracellular matrix; Liposomes; Micelles; Nanocarriers; Tumor microenvironment

Indexed keywords

MATRIX METALLOPROTEINASE;

CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; EXTRACELLULAR MATRIX; MICELLE; PH; PRIORITY JOURNAL; REVIEW; STROMA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICELLES; NEOPLASMS;

EID: 77954215975     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.020     Document Type: Review

References (113)

1. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
2. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
3. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
4. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
5. Rezler E.M., Khan D.R., Lauer-Fields J., Cudic M., Baronas-Lowell D., Fields G.B. Targeted drug delivery utilizing protein-like molecular architecture. J Am Chem Soc 2007, 129:4961-4972.
6. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009, 234:123-131.
7. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009, 100:572-579.
8. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007, 9:E128-E147.
9. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
10. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95:4607-4612.
11. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223-225.
12. Roux E., Lafleur M., Lataste E., Moreau P., Leroux J.C. On the characterization of pH-sensitive liposome/polymer complexes. Biomacromolecules 2003, 4:240-248.
13. Bianchi R., Brines M., Lauria G., Savino C., Gilardini A., Nicolini G., et al. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 2006, 12:2607-2612.
14. Wang W.S., Chiou T.J., Liu J.H., Fan F.S., Yen C.C., Chen P.M. Vincristine-induced dysphagia suggesting esophageal motor dysfunction: a case report. Jpn J Clin Oncol 2000, 30:515-518.
15. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. The Oncologist 2003, 8(Suppl. 2):3-9.
16. Swarbrick J., Boylan J. Liposomes as pharmaceutical dosage forms 1994, Encyclopedia of Pharmaceutical Dosage Forms, p. 1-39.
17. Bedu-Addo F.K., Tang P., Xu Y., Huang L. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res 1996, 13:710-717.
18. Photos P.J., Bacakova L., Discher B., Bates F.S., Discher D.E. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003, 90:323-334.
19. Bouvier M., Wiley D.C. Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules. Proc Natl Acad Sci USA 1996, 93:4583-4588.
20. Cabanes A., Even-Chen S., Zimberoff J., Barenholz Y., Kedar E., Gabizon A. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin Cancer Res 1999, 5:687-693.
21. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.
22. Roby A., Erdogan S., Torchilin V.P. Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol Ther 2007, 6:1136-1142.
23. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004, 15:517-525.
24. Lee C.C., Gillies E.R., Fox M.E., Guillaudeu S.J., Frechet J.M., Dy E.E., et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 2006, 103:16649-16654.
25. Husseini G.A., Pitt W.G. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1137-1152.
26. Hatakeyama H., Akita H., Kogure K., Oishi M., Nagasaki Y., Kihira Y., et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2007, 14:68-77.
27. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-744.
28. Wang Y.G., Wang X., Zhang Y.F., Yang S.J., Wang J.C., Zhang X., et al. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. J Drug Target 2009, 17:459-467.
29. Dennis M.S., Zhang M., Meng Y.G., Kadkhodayan M., Kirchhofer D., Combs D., et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002, 277:35035-35043.
30. Degim I.T., Celebi N. Controlled delivery of peptides and proteins. Curr Pharm Des 2007, 13:99-117.
31. Wang J., Mongayt D., Torchilin V.P. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005, 13:73-80.
32. Kabanov A.V. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 2006, 58:1597-1621.
33. Nagasaki Y., Yasugi K., Yamamoto Y., Harada A., Kataoka K. Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules. Biomacromolecules 2001, 2:1067-1070.
34. Vinogradov S., Batrakova E., Li S., Kabanov A. Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. Bioconjug Chem 1999, 10:851-860.
35. Leamon C.P., Weigl D., Hendren R.W. Folate copolymer-mediated transfection of cultured cells. Bioconjug Chem 1999, 10:947-957.
36. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003, 100:6039-6044.
37. Kim D., Lee E.S., Oh K.T., Gao Z.G., Bae Y.H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008, 4:2043-2050.
38. Xiong X.B., Mahmud A., Uludag H., Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm Res 2008, 25:2555-2566.
39. Kim S.Y., Shin I.G., Lee Y.M. Preparation and characterization of biodegradable nanospheres composed of methoxy poly(ethylene glycol) and DL-lactide block copolymer as novel drug carriers. J Control Release 1998, 56:197-208.
40. Evans D.F., Wennerstrom H. The colloidal domain: where physics, chemistry, biology, and technology meet 1994, VCH Publishers, Inc., New York.
41. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res 8:1172-1181, 2002. Clin Cancer Res 2002;8:955-6.
42. Torchilin V.P., Weissig V. Liposomes: a practical approach 2003, Oxford University Press. Second Edition.
43. New R.R.C. Liposomes: a practical approach 1990, Oxford University Press. First Edition.
44. Khan D.R., Rezler E.M., Lauer-Fields J., Fields G.B. Effects of drug hydrophobicity on liposomal stability. Chem Biol Drug Des 2008, 71:3-7.
45. Lasic D.D. Novel applications of liposomes. Trends Biotechnol 1998, 16:307-321.
46. Faassen A.E., Mooradian D.L., Tranquillo R.T., Dickinson R.B., Letourneau P.C., Oegema T.R., et al. Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-b-stimulated mouse melanoma cell motility and invasive behavior on type I collagen. J Cell Sci 1993, 105:501-511.
47. Faassen A.E., Schrager J.A., Klein D.J., Oegema T.R., Couchman J.R., McCarthy J.B. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992, 116:521-531.
48. Eliaz R.E., Szoka J.F.C. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 2001, 61:2592-2601.
49. Lee C.M., Tanaka T., Murai T., Kondo M., Kimura J., Su W., et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 2002, 62:4282-4288.
50. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001, 74:95-113.
51. Rezler E.M., Khan D.R., Tu R., Tirrell M., Fields G.B. Peptide-mediated targeting of liposomes to tumor cells. Methods Mol Biol 2007, 386:269-298.
52. Li X., Ding L., Xu Y., Wang Y., Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 2009, 373:116-123.
53. Li H., Fan X., Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007, 101:805-815.
54. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119-150.
55. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
56. Beacham D.A., Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005, 15:329-341.
57. Ghajar C.M., Bissell M.J. Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol 2008, 130:1105-1118.
58. Serebriiskii I., Castello-Cros R., Lamb A., Golemis E.A., Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol 2008, 27:573-585.
59. Rintoul R.C., Sethi T. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2001, 2:437-442.
60. Zutter M.M. Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 2007, 608:87-100.
61. Hodkinson P.S., Mackinnon A.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007, 83:733-741.
62. Li Z.W., Dalton W.S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006, 20:333-342.
63. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989, 49:4373-4384.
64. Ogiso Y., Tomida A., Tsuruo T. Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res 2002, 62:5008-5012.
65. Cosse J.P., Sermeus A., Vannuvel K., Ninane N., Raes M., Michiels C. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer 2007, 6:61.
66. Castello-Cros R., Cukierman E. Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods Mol Biol 2009, 522:275-305.
67. Pavlakis K., Messini I., Vrekoussis T., Yiannou P., Keramopoullos D., Louvrou N., et al. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions. BMC Cancer 2008, 8:88.
68. Desmouliere A., Guyot C., Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004, 48:509-517.
69. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol 2005, 167:475-488.
70. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
71. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008, 9:628-638.
72. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006, 4:38.
73. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
74. Beacham D.A., Amatangelo M.D., Cukierman E. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr Protoc Cell Biol 2007 Jan, Chapter 10:Unit 10.9. PMID: 18228495 [PubMed - indexed for MEDLINE].
75. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 2001, 294:1708-1712.
76. Castello-Cros R., Khan D.R., Simons J., Valianou M., Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009, 9:94.
77. Tunggal J.K., Cowan D.S., Shaikh H., Tannock I.F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 1999, 5:1583-1586.
78. El-Kareh A.W., Secomb T.W. Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin. Neoplasia 2005, 7:705-713.
79. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
80. DeMali K.A., Wennerberg K., Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 2003, 15:572-582.
81. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
82. Cukierman E., Pankov R., Yamada K.M. Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 2002, 14:633-639.
83. Aoudjit F., Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
84. Robey I.F., Baggett B.K., Kirkpatrick N.D., Roe D.J., Dosescu J., Sloane B.F., et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009, 69:2260-2268.
85. Raghunand N., Gillies R.J. pH and drug resistance in tumors. Drug Resist Updat 2000, 3:39-47.
86. Gerweck L.E., Vijayappa S., Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006, 5:1275-1279.
87. Raghunand N., He X., van Sluis R., Mahoney B., Baggett B., Taylor C.W., et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999, 80:1005-1011.
88. Luciani F., Spada M., De Milito A., Molinari A., Rivoltini L., Montinaro A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004, 96:1702-1713.
89. Lee C.M., Tannock I.F. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 2006, 94:863-869.
90. Kim D., Gao Z.G., Lee E.S., Bae Y.H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharmaceutics 2009, 6:1353-1362.
91. Gillies E.R., Frechet J.M. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 2005, 16:361-368.
92. Gillies E.R., Jonsson T.B., Frechet J.M. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J Am Chem Soc 2004, 126:11936-11943.
93. Boomer J.A., Thompson D.H. Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications. Chem Phys Lipids 1999, 99:145-153.
94. Qualls M.M., Thompson D.H. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: intracellular localization and synergistic phototoxicity. Int J Cancer 2001, 93:384-392.
95. Guo X., Szoka F.C. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res 2003, 36:335-341.
96. Huang Z., Guo X., Li W., MacKay J.A., Szoka F.C. Acid-triggered transformation of diortho ester phosphocholine liposome. J Am Chem Soc 2006, 128:60-61.
97. Chen Q.R., Zhang L., Stass S.A., Mixson A.J. Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes. Gene Ther 2000, 7:1698-1705.
98. Woessner J.F., Nagase H. Matrix metalloproteinases and TIMPs 2000, Oxford University Press, Oxford.
99. Kline T., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Senter P.D. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9. Mol Pharmaceutics 2004, 1:9-22.
100. Chau Y., Tan F.E., Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem 2004, 15:931-941.
101. Terada T., Iwai M., Kawakami S., Yamashita F., Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release 2006, 111:333-342.
102. Sarkar N.R., Rosendahl T., Krueger A.B., Banerjee A.L., Benton K., Mallik S., et al. Uncorking of liposomes by matrix metalloproteinase-9. Chem Commun 2005, 999-1001.
103. Elegbede A.I., Banerjee J., Hanson A.J., Tobwala S., Ganguli B., Wang R., et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc 2008, 130:10633-10642.
104. Gray M.D., Mann M., Nitiss J.L., Hendershot L.M. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol 2005, 68:1699-1707.
105. Tomida A., Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999, 14:169-177.
106. Greijer A.E., van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004, 57:1009-1014.
107. Gandara D.R., Lara P.N., Goldberg Z., Le Q.T., Mack P.C., Lau D.H., et al. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 2002, 29:102-109.
108. Hong R.-L., Huang C.-J., Tseng Y.-L., Pang V.F., Chen S.-T., Liu J.-J., et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor bearing mice: is surface coating with polyethylene glycol beneficial?. Clin Cancer Res 1999, 5:3645-3652.
109. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
110. Tremblay M.R., Lescarbeau A., Grogan M.J., Tan E., Lin G., Austad B.C., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009, 52:4400-4418.
111. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006, 7:211-224.
112. Kleinman H.K., Martin G.R. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005, 15:378-386.
113. Grinnell F., Rocha L.B., Iucu C., Rhee S., Jiang H. Nested collagen matrices: a new model to study migration of human fibroblast populations in three dimensions. Exp Cell Res 2006, 312:86-94.